Loading...
XTSEHLS
Market cap85mUSD
Dec 24, Last price  
3.87CAD
1D
3.20%
1Q
10.57%
Name

HLS Therapeutics Inc

Chart & Performance

D1W1MN
XTSE:HLS chart
P/E
—
P/S
1.36
EPS
—
Div Yield, %
1.95%
Shrs. gr., 5y
3.66%
Rev. gr., 5y
0.53%
Revenues
63m
+2.61%
77,808,74168,202,16949,661,118100,588,71068,147,08271,875,65688,098,90478,746,327116,555,59279,465,98773,877,12519,956,00054,031,00075,082,00061,415,00054,160,00056,109,00060,009,00061,467,00063,074,000
Net income
-28m
L+16.67%
09,507,4901,310,0547,594,66802,553,719011,983,34916,867,2039,732,61812,717,29500-6,097,000-24,806,000-19,552,000-15,331,000-13,117,000-23,598,000-27,531,000
CFO
16m
-6.81%
2,488,06212,500,430703,50021,977,1785,554,6425,323,27325,063,98917,918,70721,230,76318,031,12418,208,9140027,166,00032,747,00026,408,0009,344,00016,429,00016,942,00015,789,000
Dividend
Apr 27, 20230.05 CAD/sh
Earnings
Mar 12, 2025

Profile

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
URL
https://www.hlstherapeutics.com/
IPO date
Mar 17, 1980
Employees
99
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
63,074
2.61%
61,467
2.43%
60,009
6.95%
Cost of revenue
35,910
40,562
36,029
Unusual Expense (Income)
NOPBT
27,164
20,905
23,980
NOPBT Margin
43.07%
34.01%
39.96%
Operating Taxes
(272)
(124)
1,309
Tax Rate
5.46%
NOPAT
27,436
21,029
22,671
Net income
(27,531)
16.67%
(23,598)
79.90%
(13,117)
-14.44%
Dividends
(2,398)
(4,962)
(5,122)
Dividend yield
1.88%
1.56%
1.06%
Proceeds from repurchase of equity
(1,552)
(998)
(47)
BB yield
1.22%
0.31%
0.01%
Debt
Debt current
5,156
13,584
12,606
Long-term debt
83,349
84,771
86,392
Deferred revenue
Other long-term liabilities
2,210
817
1,884
Net debt
66,553
77,632
77,819
Cash flow
Cash from operating activities
15,789
16,942
16,429
CAPEX
(41)
(10,148)
(4,510)
Cash from investing activities
(189)
(10,148)
(4,510)
Cash from financing activities
(14,639)
(6,856)
(11,398)
FCF
32,751
22,932
14,980
Balance
Cash
21,952
20,723
21,179
Long term investments
Excess cash
18,798
17,650
18,179
Stockholders' equity
83,832
111,497
149,019
Invested Capital
168,730
205,830
241,910
ROIC
14.65%
9.39%
9.03%
ROCE
14.49%
9.33%
9.20%
EV
Common stock shares outstanding
32,263
32,433
32,184
Price
3.95
-59.82%
9.83
-34.47%
15.00
-16.67%
Market cap
127,440
-60.03%
318,815
-33.96%
482,761
-15.43%
EV
193,993
396,447
560,580
EBITDA
59,103
55,307
54,244
EV/EBITDA
3.28
7.17
10.33
Interest
8,748
7,317
6,956
Interest/NOPBT
32.20%
35.00%
29.01%